Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31183085 | 0.89 | GRM5 (0.41) | GRM5AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL21223327 | 0.89 | GRM5 (0.41) | GRM5AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL31247610 | 0.80 | CHRNB2 (0.39) | GRM5CHRNB2CHRNA4CYP1A2TSHR | |
| SCHEMBL12891722 | 0.79 | CHRNB2 (0.38) | GRM5CHRNB2CHRNA4 | |
| SCHEMBL29364445 | 0.79 | CHRNB2 (0.38) | GRM5CHRNB2CHRNA4CYP1A2TSHR | |
| SCHEMBL14614714 | 0.79 | CHRNB2 (0.38) | GRM5CHRNB2CHRNA4CYP1A2TSHR | |
| SCHEMBL14614599 | 0.79 | CHRNB2 (0.38) | GRM5CHRNB2CHRNA4CYP1A2TSHR | |
| SCHEMBL18795872 | 0.79 | CHRNB2 (0.38) | GRM5CHRNB2CHRNA4CYP1A2TSHR | |
| SCHEMBL12891724 | 0.79 | CHRNB2 (0.38) | GRM5CHRNB2CHRNA4 | |
| SCHEMBL25693008 | 0.79 | GRM5 (0.52) | GRM5AURKADAPK3PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250241905-A1 | 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-12358904-B2 | Inhibitors of TYK2 | Atomwise Inc. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4543437-A1 | 3-?HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20240425484-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-26 | — | — | US | disclosed |
| US-20240417396-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-19 | — | — | US | disclosed |
| WO-2024250010-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-11992489-B2 | Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-05-28 | — | — | US | disclosed |
| EP-3836928-B1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2020036837-A1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-10100048-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-10-16 | — | — | US | disclosed |
| CN-108430972-A | α, β unsaturated acyl amine compounds | 协和发酵麒麟株式会社 | 2018-08-21 | — | — | CN | disclosed |
| EP-2621914-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2016-12-28 | — | — | EP | disclosed |
| US-20160194320-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2016-07-07 | — | — | US | disclosed |
| US-9266855-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-02-23 | — | — | US | disclosed |
| US-20160016932-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-21 | — | — | US | disclosed |
| EP-2621914-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041814-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-20120077840-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194320-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | GRM5 3497/4885AURKA 338/4885DAPK3 25/4885 |
| US-11992489-B2 | Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | GRM5 1061/4885AURKA 3889/4885DAPK3 1731/4885 |
| US-20240417396-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | GRM5 2396/4885AURKA 150/4885DAPK3 177/4885 |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | GRM5 1437/4885AURKA 1353/4885DAPK3 293/4885 |
| US-20160016932-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | GRM5 3497/4885AURKA 338/4885DAPK3 25/4885 |
| US-20250241905-A1 | 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF | HSD3B1, HSD3B2, HSD17B11 | GRM5 2725/4885AURKA 4178/4885DAPK3 1054/4885 |
| US-12358904-B2 | Inhibitors of TYK2 | TYK2, LCK, JAK2 | GRM5 2396/4885AURKA 150/4885DAPK3 177/4885 |
| US-20120077840-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | GRM5 3497/4885AURKA 338/4885DAPK3 25/4885 |
| US-10100048-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | GSK3B, GSK3A, GYS2 | GRM5 3497/4885AURKA 338/4885DAPK3 25/4885 |
| US-20240425484-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | GRM5 2396/4885AURKA 150/4885DAPK3 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.